IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients

Dany A. Curi(Northwestern University), Nobuko Hijiya(Lurie Children's Hospital), Jennifer Schneiderman(Northwestern University), Sonali Chaudhury(Northwestern University), Jonathan B. Bell(Northwestern University), Colleen M. Badke(Northwestern University), R. Duerst(Northwestern University), Morris Kletzel(Lurie Children's Hospital), William Tse(Lurie Children's Hospital), William J. Muller(Lurie Children's Hospital)
Bone Marrow Transplantation
May 23, 2016
10.1038/bmt.2016.133
Cited by 10

Related Papers

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia
|JAMA|2007|314
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248
Ancestry and pharmacogenetics of antileukemic drug toxicity
|Blood|2007|207
Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
|Transplantation and Cellular Therapy|2012|201